Skip to content

TRANS-FOODS: Preventing Peanut Allergy Through Improved Understanding of the Transcutaneous Sensitisation Route, Novel Food Processing and Skin Care Adaptations

TRANS-FOODS: Preventing Peanut Allergy Through Improved Understanding of the Transcutaneous Sensitisation Route, Novel Food Processing and Skin Care Adaptations

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05407012
Acronym
TRANS-FOODS
Enrollment
120
Registered
2022-06-07
Start date
2024-04-05
Completion date
2025-05-31
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy;Food, Food Allergy Peanut, Pathways and Sources of Exposure

Keywords

Allergy, Food safety, Public health, Dermatology, Food manufacture

Brief summary

This project aims to study the immune responses to peanut allergen in those with a skin barrier defect with and without skin massage, specifically it aims to: 1. Establish if peanut allergen components can pass into human skin through regular massage using the peanut protein-containing extract. 2. Clarify whether this effect is amplified in those with an impaired skin barrier (AD and dry skin vs healthy controls). 3. Assess whether peanut protein components can be detected in interstitial skin fluid (ISF) using a suction device. 4. Test whether peanut protein components present in ISF are able to induce activation of basophils in blood of peanut allergic donors. 5. Assess whether the transcutaneous uptake of peanut protein can be reduced by the prior use of a barrier enhancing cream.

Detailed description

The study aims to understand how peanut processing methods and peanut co-administration with oils, as is standard during the industrial processing of peanuts, influences the development of peanut allergy through the skin. Cutaneous exposure of allergens is a crucial, but hitherto under explored route of food sensitisation, that if understood could lead to the development of translatable strategies to prevent food allergy. Food processors require a greater understanding of how allergen exposure cause allergy so that they can adapt their processing methods to counteract these exposure processes. Furthermore, this proposed research aligns with on-going efforts across Europe to address the increasing problems associated with food allergy but it is unique in that it focuses on cutaneous allergen exposure, which is a field in desperate need of more systematic study. The assembled team of investigators (from the UK, Germany and France) joined by a peanut industry partner (Levantine) and patient and consumer representatives will aim to address the following hypotheses: Understanding the mechanisms by which: * Peanut proteins pass into the skin via the appendages to trigger an immune response. * Skin stretching that occurs during massage opens up the skin appendages allowing more peanut protein into the skin and leads to dendritic cell activation and induction of T helper 2 cell response. * Co-administration of peanut proteins and an oil to the skin increases allergenicity. * Skin barrier impairment and inflammation (AD) increases allergenicity. Test novel approaches to peanut allergy prevention whereby: * Modifications in peanut processing can reduce allergen exposure via the skin. * Meticulous hand hygiene reduces skin contamination with peanut protein. * Application of a barrier enhancing cream can strengthen the skin barrier, in particular in those with atopic dermatitis, and reduce the risk of transcutaneous sensitisation further.

Interventions

OTHERApplication of the barrier enhancing preparation.

Application of the barrier enhancing preparation around 30 minutes before application of the peanut protein extract +/- massage after extract application;

Sponsors

University Hospital, Bonn
CollaboratorOTHER
Institut Curie
CollaboratorOTHER
Charite University, Berlin, Germany
CollaboratorOTHER
Levantine UK
CollaboratorUNKNOWN
King's College London
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Adult healthy volunteers (50% of the cohort), and adults with dry skin and AD (fulfilling the refined Hanifin and Rajka criteria, 50% of the cohort). * Willingness to apply the study intervention and to not use any other topical preparations over theforearms during the study period.

Exclusion criteria

* History of peanut allergy. * Positive skin prick test to peanut (\>0 mm). * No regular consumption of peanut products. * Widespread AD, in particular if this involves the test sites of the forearms.

Design outcomes

Primary

MeasureTime frameDescription
Detection of peanut protein components (μg of the proteins per cm² of skin) in retrieved interstitial fluid.8 weeksDetection of peanut protein components (μg of the proteins per cm² of skin) in retrieved interstitial fluid.
Activation of blood basophil from peanut allergic donors (measured as %CD63-positive basophils) by peanut proteins present in interstitial fluid.8 weeksActivation of blood basophil from peanut allergic donors (measured as %CD63-positive basophils) by peanut proteins present in interstitial fluid.

Secondary

MeasureTime frameDescription
Detection of inflammatory cytokine markers (IL-4, IL-13, IL-33 and TSLP) in interstitial fluid.8 weeksDetection of inflammatory cytokine markers (IL-4, IL-13, IL-33 and TSLP) in interstitial fluid.
Raised transepidermal water loss.8 weeksRaised transepidermal water loss.

Other

MeasureTime frameDescription
Assess skin barrier function measures (skin surface pH).8 weeksAssess skin barrier function measures (skin surface pH).

Countries

United Kingdom

Contacts

Primary ContactStuart Jones
stuart.jones@kcl.ac.uk0207 848 4506

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026